Cancer Vaccines in the Immunotherapy Era: Promise and Potential

Author:

Verma Chaitenya1ORCID,Pawar Vishakha Anand2ORCID,Srivastava Shivani3ORCID,Tyagi Anuradha4ORCID,Kaushik Gaurav5,Shukla Surendra Kumar6,Kumar Vinay7ORCID

Affiliation:

1. Department of Pathology, Wexner Medical Center, Ohio State University, Columbus, OH 43210, USA

2. The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

3. Department of Pathology, School of Medicine, Yale University, New Haven, CT 06510, USA

4. Department of cBRN, Institute of Nuclear Medicine and Allied Science, Delhi 110054, India

5. School of Allied Health Sciences, Sharda University, Greater Noida 201310, India

6. Department of Oncology Science, OU Health Stephenson Cancer Center, Oklahoma City, OK 73104, USA

7. Department of Physiology and Cell Biology, The Ohio State University Wexner Medical Center, Columbus, OH 43201, USA

Abstract

Therapeutic vaccines are a promising alternative for active immunotherapy for different types of cancers. Therapeutic cancer vaccines aim to prevent immune system responses that are not targeted at the tumors only, but also boost the anti-tumor immunity and promote regression or eradication of the malignancy without, or with minimal, adverse events. Clinical trial data have pushed the development of cancer vaccines forward, and the US Food and Drug Administration authorized the first therapeutic cancer vaccine. In the present review, we discuss the various types of cancer vaccines and different approaches for the development of therapeutic cancer vaccines, along with the current state of knowledge and future prospects. We also discuss how tumor-induced immune suppression limits the effectiveness of therapeutic vaccinations, and strategies to overcome this barrier to design efficacious, long-lasting anti-tumor immune responses in the generation of vaccines.

Funder

National Institute of General Medical Sciences of the National Institutes of Health

Publisher

MDPI AG

Subject

Pharmacology (medical),Infectious Diseases,Drug Discovery,Pharmacology,Immunology

Reference148 articles.

Cited by 3 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

1. Prophylactic and therapeutic cancer vaccine with continuous localized immunomodulation;Nanomedicine: Nanotechnology, Biology and Medicine;2024-11

2. Exploring Cancer Immunotherapy and the Promise of Cancer Vaccine;Advances in Medical Diagnosis, Treatment, and Care;2024-08-28

3. Nerve Growth Factor and the Role of Inflammation in Tumor Development;Current Issues in Molecular Biology;2024-01-23

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3